Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Paradium AI (PAAI) Halted, News Pending
Charles River Laboratories (CRL) shares plunge after Justice Department subpoena relating to NHPs
February 22, 2023 12:16 PM ESTCharles River Laboratories (NYSE: CRL) shares plummeted over 14% Wednesday after the company said in its latest earnings report that it has received a subpoena from the U.S. Department of Justice in connection with an investigation into the Cambodian non-human primate (NHP) supply... More
Charles River Laboratories (CRL) Tops Q4 EPS by 23c; Guides FY23 EPS Below Views
February 22, 2023 7:06 AM ESTCharles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.98, $0.23 better than the analyst estimate of $2.75. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.04 billion.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $9.70-$10.90. Charles River... More
